This is supported by recent evidence indicating that dupilumab provides comparable, if not superior, improvements in asthma control test (ACT) scores compared with intraclass switching following inadequate response to anti-IL-5 or anti-IL-5R monoclonal antibodies [21]. This evidence concerns the gene IL5 and asthma.